Dr. Gadgeel joined Michigan Medicine in 2017 to advance the care of lung cancer patients with a combined emphasis on clinical trials and research. As treatment options for lung cancer patients expand, he has never felt more hopeful that an increasing number of patients will benefit from positive results. He believes the University of Michigan Rogel Cancer Center is uniquely positioned to advance care through the collaboration and expertise of its medical faculty and research scientists, which enable us to conduct and execute clinical trials that might not be possible at other cancer centers.
Dr. Gadgeel treats patients at the University of Michigan Rogel Cancer Center in Ann Arbor, as well as the Northville Health Center, making it easier for Metro-Detroit area patients to obtain care closer to home during a time when driving long distances can be a challenge. He plans to use the wider treatment area as a way to include more patients in lung cancer clinical trials for new treatments, such as immunotherapy and targeted therapy.
Dr. Gadgeel is the Mary Lou Kennedy Research Professor in Thoracic Oncology and a professor in the Department of Internal Medicine’s Division of Hematology/Oncology. He is the co-leader of the Thoracic Oncology Research Program and associate director for cancer care at Networking and Affiliated Centers. He has served on a number of committees, including ASCO’s education committee and as a mentor for the International and Development and Education Award (IDEA) program. He is a member of the executive committee for lung cancer at SWOG.
Dr. Gadgeel serves on the editorial boards of “Cancer” and “Clinical Lung Cancer,” and has published extensively in a number of additional peer-reviewed journals.
Br J Cancer. 2017 Nov 16. doi: 10.1038/bjc.2017.395. [Epub ahead of print]
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Gadgeel S1, Shaw AT2, Barlesi F3, Crinò L4, Yang JC5, Dingemans AC6, Kim DW7, de Marinis F8, Schulz M9, Liu S9, Gupta R9, Kotb A10, Ou SI11.
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S1, Camidge DR1, Shaw AT1, Gadgeel S1, Ahn JS1, Kim DW1, Ou SI1, Pérol M1, Dziadziuszko R1, Rosell R1, Zeaiter A1, Mitry E1, Golding S1, Balas B1, Noe J1, Morcos PN1, Mok T1; ALEX Trial Investigators.
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A1, Barlesi F2, Waterkamp D3, Park K4, Ciardiello F5, von Pawel J6, Gadgeel SM7, Hida T8, Kowalski DM9, Dols MC10, Cortinovis DL11, Leach J12, Polikoff J13, Barrios C14, Kabbinavar F15, Frontera OA16, De Marinis F17, Turna H18, Lee JS19, Ballinger M3, Kowanetz M3, He P3, Chen DS3, Sandler A3, Gandara DR20; OAK Study Group.
Am Soc Clin Oncol Educ Book. 2017;37:630-639. doi: 10.14694/EDBK_175188.
Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer.
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ1, Gadgeel SM2, Borghaei H3, Papadimitrakopoulou VA4, Patnaik A5, Powell SF6, Gentzler RD7, Martins RG8, Stevenson JP9, Jalal SI10, Panwalkar A11, Yang JC12, Gubens M13, Sequist LV14, Awad MM15, Fiore J16, Ge Y16, Raftopoulos H16, Gandhi L17; KEYNOTE-021 investigators.